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ABSTRACT
Objective: The goal of this study was to formulate ticagrelor tablets with enhanced dissolution rate using cogrinding technique. However, it belongs 
to the biopharmaceutical classification system Class IV molecule, poorly soluble, and permeable.
Methods: Various ratios (0.2:1–1.67:1) of povidone (PVP)/drug were used in the formulations. Ticagrelor was coground with different percentage 
of PVP K 25 (carrier) in a mortar with a pestle for 30 min, then mixed with the rest excipients. A high-performance liquid chromatography stability 
indicating assay was developed to test the stability of ticagrelor in the selected formulae.
Results: The results showed that the presence of  PVP in relatively high ratios compared to the drug is desirable for enhancing the dissolution rate of 
ticagrelor. The best-optimized formulae found were that F8 and F9 which showed good disintegration and dissolution rate of ticagrelor more than 92% after 
30 min while the dissolution rate for ticagrelor standard was only 22% after 30 min. Stability studies were performed on the selected formulae F8 and F9.
Conclusion: The optimized formulae were evaluated for thickness, weight variation, hardness, friability, dissolution, and accelerated stability study 
for a period of 6 months. Cogrinding using PVP K 25 proved to enhance the dissolution of ticagrelor which may be due to the formation of a soluble 
complex between ticagrelor and PVP. The selected formulae F8 and F9 showed good stability.
Keywords: Ticagrelor, Stability indicating assay, Poorly soluble drug, Cogrinding.
INTRODUCTION
Ticagrelor is used for the prevention of thrombotic events in patients 
with acute coronary syndromes. The absolute bioavailability of 
ticagrelor is in the range 30–42% [1,2]. The chemical structure of 
ticagrelor is shown in Fig. 1.
Ticagrelor is a crystalline powder with an aqueous solubility of 
approximately 10 µg/mL at room temperature. Ticagrelor exhibits no 
pKa value within the physiological range. Ticagrelor does not exhibit 
pH-dependent solubility. Its melting point is about 140°C–142°C as 
measured by differential scanning calorimetry. Partition coefficient 
of ticagrelor exhibits a log P (octanol/water) >4.0. Optical rotation of 
1% w/v ticagrelor in ethanol is approximately −52° [3].
Ticagrelor belongs to the biopharmaceutical classification system 
(BCS) Class IV molecule which means that it is poorly soluble and has 
low permeability [4]. Hence, it is important to increase its solubility. 
Hence, dissolution rate and bioavailability will increase.
Improvement of the dissolution rate and the bioavailability of poorly 
soluble drugs can be achieved by preparing solid dispersions using 
some polymers such as polyethylene glycol 6000, inclusion complexes 
using β-cyclodextrin,  hydroxypropyl-βcyclodextrin,  liquisolid  systems 
using nonvolatile solvent, carrier, and the coating material [5,6].
Furthermore, nanocrystals, spray drying, chitosan-based solvent change 
approach, preparation of dry elixir, and amorphous systems are used to 
enhance the dissolution rate of poorly soluble drugs [7]. Co-grinding is one 
of the solid dispersion techniques but it has some additional advantages 
over other approaches as it is simple, cheap, does not require any toxic 
organic solvents [8] and can be applied easily in the industry. Cogrinding 
technique has already been applied to some drugs such as phenytoin 
[9], furosemide [10], and glibenclamide [11]. However, the method of 
cogrinding for the preparation of ticagrelor has not been reported in the 
literature. Povidone (PVP) was chosen as a carrier for its capability of 
forming water-soluble complex with some poorly soluble drugs [12].
MATERIALS AND METHODS
Materials
Ticagrelor purchased from Virdev, India, lactose direct compression 
(lactose DC), croscarmellose sodium (Ac-di-sol), magnesium stearate 
and PVP K 25; kindly supplied by Elkahira Pharmaceutical Chemicals 
Company, Shoubra, Cairo, Egypt. Acetonitrile for high-performance 
liquid chromatography (HPLC) was purchased from Merck, Darmstadt, 
Germany. Hydrochloric acid, phosphoric acid, potassium dihydrogen 
phosphate, sodium hydroxide pellets, and hydrogen peroxide 30% 
were purchased from El-Nasr Pharmaceutical Chemicals Company, 
Cairo, Egypt. High purity water was prepared using a Waters Milli-Q 
plus purification system.
Methodology
A stability indicating assay is developed and validated to determine 
drug content of ticagrelor and in stability studies. Furthermore, UV-VIS 
method was developed to determine percent dissolved of ticagrelor in 
fresh samples.
Development and validation of a HPLC stability indicating assay
Preparation of standard solution
40 mg of ticagrelor was weighed accurately and transferred into a 
100 ml measuring flask, 50 ml methanol was added, shaken to dissolve 
by sonication for 5 min, completed to the volume with methanol and 
mixed well.
Preparation of test solution
Ten tablets were weighed, and the average weight of one tablet was 
found out and ground. A weight of powdered tablet equivalent to the 
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weight of one tablet was transferred into a 100 ml volumetric flask, 
about 50 ml methanol was added, sonicated for 15 min, completed 
to volume using methanol, mixed well and filtered through 0.45 µm 
membrane filter.
Chromatographic conditions
The  separation  was  achieved  using  a  Kromasil  C18  (5  μm, 
25 cm × 4.6 mm) column, a Waters HPLC apparatus consisting of pump 
1525 and a UV/VIS detector 2487. The injection volume was 20 µl 
and a mobile phase consisting of phosphate buffer pH 3:acetonitrile 
(50:50 v/v) while at a flow-rate of 1.0 ml/min. Ticagrelor was detected 
at 254 nm. Linearity range was 30–90 μg/ml. The method was validated.
Method validation
The developed method was validated to establish the specificity, 
precision, linearity, accuracy, and robustness according to the United 
States Pharmacopeia (USP) [13], Food and Drug Administration 
(FDA) [14], and International Conference Harmonization (ICH) 
guidelines [15].
Linearity
The calibration curve of the drug concentrations was constructed. The 
regression equation, the correlation coefficient, slope of the regression 
line, and residual standard deviation (σ) were calculated.
Specificity
The terms specificity and selectivity are often used interchangeably as 
both the USP and ICH [16] currently use the term specificity, it will also 
be used here to avoid any confusion. The USP [13] defines specificity 
as the ability to measure accurately and specifically the analyte of 
interest in the presence of other components in the sample matrix. 
These components may include other active ingredients, excipients, 
impurities, and degradation products.
Stress degradation studies
All the reagents used for degradation study (stressors), i.e. 0.1N HCl, 
0.1N NaOH, and 30% (w/v) H2O2. The drug was subjected to forced 
degradation until optimum degradation (10–30%) was achieved.
Accuracy
Accuracy is the measure of the closeness of the experimental value to 
the true value. It should be established across the specified range (that 
is, the line of working range) of the analytical procedure.
Precision
Precision is the measure of how close the data values are to each other 
for a number of measurements under the same analytical conditions 
or “the degree of agreement among individual test results obtained by 
repeatedly applying the analytical method to multiple samplings of a 
homogeneous sample.”
Repeatability
Six test solutions having all 100% of the test were prepared following 
the test preparation procedure in the analytical method. The results 
obtained were calculated, relative standard deviation (RSD) should not 
be more than ±1 as FDA [14] recommendations.
Ruggedness (Intermediate precision)
Intermediate precision expresses within-laboratory variations. This was 
previously evaluated as part of ruggedness to evaluate the reliability of 
the method. The data obtained from the interday and intraday confirm 
the ruggedness of the used analytical method.
Robustness
The robustness of an analytical procedure is a measure of its capacity 
to remain unaffected by small but deliberate variations in some 
parameters and provide an assurance of its reliability during normal 
usage. The robustness of the method is investigated by varying some 
or all conditions, for example, the organic composition of the mobile 
phase, pH, ionic strength, column temperature, the age of column, 
and column type. ICH [15] guidelines recommend that robustness 
studies should be performed during the method development stage. 
Robustness can also be partly assured by good system suitability 
specification. Therefore, it is important to set tight but realistic system 
suitability specifications. Robustness of the method was investigated by 
changing the instrumental conditions such as flow rate (±10%), column 
oven temperature (±5%), the wavelength of detection (±5 nm), organic 
content in mobile phase (±2%), and pH of the buffer in mobile phase 
(±0.2 units).
The lower limit of detection (LOD)
The lower LOD is the lowest concentration of the analyte that can 
be detected, but has not necessarily quantitated, under the stated 
experimental conditions and could be calculated according to the formula:
LOD=3.3σ÷S
Where σ is the standard deviation of residuals, S is the slope of the line 
of the calibration curve [16].
The lower limit of quantitation (LOQ)
The lower LOQ is the lowest concentration of the analyte that can be 
determined with acceptable precision and accuracy under the stated 




of the calibration curve [16].
System suitability
The system suitability specifications are parameters that provide 
assistance in achieving this purpose. According to the ICH [15] and the 
USP [13], system suitability tests are performed before the analysis 
of the actual samples. Parameters required, such as tailing factor (T) 
should be for ticagrelor not be more than 2, resolution (RS) should be 
more than 2 if there is more than one peak, capacity factor (k’) should be 
more than 2, and plate count should be not <2000 [17,18] Figs. 1 and 2.
UV-VIS method development
UV-VIS method developed for the determination of ticagrelor in 
dissolution rate of ticagrelor fresh tablets.
Standard solution preparation
200 mg of ticagrelor was accurately weighed and transferred into 
100 ml volumetric flask, 5 ml methanol was added and shaken for 5 min 
Fig. 1: Chemical structure of ticagrelor
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to dissolve, completed to the volume using 0.3 % tween 80 in 0.1 N 
HCl, mixed well then diluted to give serial concentrations of ticagrelor 
in the range of 2–12 μg/ml in 0.3% tween 80 in 0.1 N HCl, scanned in 
the range of 200–500 nm (Shimadzu UV 1700 system in the range of 
200–500 nm with 1 cm matched quartz cells) using 0.3% tween 80 in 
0.1 N HCl as a blank, and λ 298 nm was chosen to be the maximum λmax.
Preparation of test solution
Ten tablets were weighed, and the average weight was found out of one 
tablet, ground. A weight of powdered tablet equivalent to the weight of 
one tablet was transferred into a 100 ml volumetric flask, about 5 ml 
methanol was added and shaken for 10 min, completed to volume using 
0.3% tween 80 in 0.1 N HCl, mixed well and filtered through 0.45 µm 
membrane filter. Then, diluted to give serial concentrations of ticagrelor 
in the range of 2–12 μg/ml in 0.3% tween 80 in 0.1 N HCl, measured at 
λmax 298 nm which was predetermined. The percent of ticagrelor was 
determined by substituting the regression equation Figs, 4 and 5.
Tablets preparation
Ticagrelor was coground with different percentage of PVP K 25 (carrier) 
in a mortar with a pestle for 30 min and sieved on a sieve mesh size 
125 μm then was mixed with lactose DC, sieved through a 600 μm sieve 
and mixed for 3 min. Then, the previous powder blend was mixed with 
Ac-Di-Sol, sieved through a 600 μm sieve and mixed for 3min. Finally, 
lubricant (magnesium stearate) was sieved through a 600 μm sieve and 
mixed with the previous blend for 1 min.
The tablets were compressed on flat punch 9 mm. All tablets were 
compressed into 300 mg using a single punch tablet machine (Erweka, 
Germany). The force of compression was kept constant throughout the 
compression process (Table 1).
Evaluation of post-compression properties
Weight variation
Twenty tablets, from each formula, were individually weighed 
(Sartorius, Gottingen, Germany). The mean weight of tablets was 
calculated [14].
Content uniformity
The uniformity of content was determined by crushing 10 tablets 
from each formula and determining the drug content of each tablet 
individually using the developed HPLC method [13].
Friability
Ten tablets from each formula were accurately weighed and placed 
in the drum of a friablator (Pharma Test, Germany), which rotated 
at 25 rpm for a period of 4 min. The tablets were then brushed and 
reweighed. The percentage loss in weights was calculated and taken as 
a measure of friability [13].
Hardness
Ten tablets from each formula were tested for their hardness (Tablet 
Hardness Tester, Erweka, Germany). The mean hardness in kilograms 
was then determined [13].
Disintegration time
The disintegration time for each of six tablets from each formula was 
determined using USP Disintegration Tester (USP Disintegration, 
Pharma Test, Germany) [13].
In vitro dissolution studies
The test was performed in 0.3% tween 80 in 0.1 N HCl solution at a 
temperature of 37°C ±0.5 using the USP Dissolution Tester (Dissolution 
Apparatus Validata SR 6, Hanson Research Corporation, USA). 
Apparatus II (paddle), at a rotation of 75 rpm [19]. Aliquots, each of 
5 ml of the dissolution medium were withdrawn at 5, 10, 20, 30, and 
45 min intervals. The samples withdrawn were then filtered, adequately 
Fig. 2: High-performance liquid chromatography spectrum of 
ticagrelor
Fig. 4: UV spectrum of ticagrelor
Fig. 3: Graph representing the calibration curve of high-performance 
liquid chromatography method for ticagrelor. Error bars represent 
the standard deviation of the mean (±standard deviation)
Fig. 5: Graph representing the calibration curve of UV-VIS method 
for ticagrelor. Error bars represent the standard deviation of the 
mean (±standard deviation)
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diluted and analyzed for ticagrelor content by measuring absorbance at 
λ 298 nm using 0.3% tween 80 in 0.1 N HCl as a blank. A similar volume 
of 0.3% tween 80 in 0.1 N HCl was added to the dissolution medium to 
maintain sink conditions, and correction factor was included [20].
Stability studies
Stress testing should be done at 40°C/75% RH for 6 months. If a 
significant change occurs at these stress condition, then the formulation 
should be tested at 30°C/65% RH for 6 months as intermediate 
conditions. Stability studies should be done on tablets in its final package.
RESULTS AND DISCUSSION
The method was found to be specific, precise, sensitive, and stability 
indicating. The correlation coefficient (r2) was found to be >0.999 which 
was within the limits specified (NLT 0.99) showed good linearity. The 
recovery was found to be in the range of 98–102% indicates that this 
method can be used for quantitative routine quality control analysis of 
pharmaceutical dosage forms. The precision of a method determines the 
closeness of agreement between a series of measurements of the same 
sample. The RSD values were found to be 0.1% –0.12 %. These values 
were well within the generally accepted limit of <2%. Hence, confirming 
the good precision of the assay method. The sensitivity of the method 
was measured by calculating the LOD and limit of quantification [21]. 
LOD and LOQ were calculated using GraphPad InStat® to be 2.97µg/ml 
and 9 μg/ml, respectively.
The UV-VIS method was applied and showed to be suitable for 
determination of ticagrelor dissolved percent in fresh samples. 
Formulations post-compression properties were shown in Table 2. 
All Formulations were evaluated for weight variation and results 
indicated very low weight variation which lies within pharmacopeia 
limits, i.e. ±5%. Hardness was seen to be in the range of values of 
4.8–8.3 kg/cm3, friability of all formulae was <1%, and the disintegration 
time of formulae F1-F9 tablets was in the range of 0.5–3 min.
The dissolution rate of ticagrelor from F7, F8, F9, F10, and F11 
formulae where the ratios of PVP K 25 to ticagrelor ranged from 0.8:1 
to 1.67:1, ticagrelor released was 81%, 92.1%, 93.5%, 92%, and 93.2%, 
respectively, after 30 min while the dissolution rate for ticagrelor 
standard which was only 22% was shown in Fig. 2.
The formulae F8 and F9 were selected for being stability tested in 
its final package at 40°C/75% RH for 6 months and were shown to 
be stable all over the study using the developed validated proposed 
stability indicating assay.
In comparison with the previous studies of researchers such as Ramesh 
et al. [22] who enhanced the solubility and the dissolution rate of 
ticagrelor by solvent evaporation solid dispersion technique. The 
maximum improvement of the dissolution rate was 72.5% after 30 min 
while in this study the dissolution rate was more than 92% after 30 min 
in the formulae F8 and F9. Furthermore, Ramesh et al. [22] reached 
95.2% drug content as the maximum result while in this work, the 
minimum drug content obtained was 98.57%.
Dabhi et al. [23] tried to increase the dissolution rate of ticagrelor 
using solid dispersion made by spray drying in which a solid dispersion 
Fig. 6: Dissolution profile of ticagrelor from prepared tablets 
(values represent mean±standard deviation, n=6)
Table 1: Formulae of ticagrelor prepared tablets
Formulae Ticagrelor (mg) Povidone (mg) Carrier/drug ratio Lactose DC (mg) Ac-di-sol (mg) Mg stearate (mg)
F1 90 18 0.2:1 156 30 6
F2 90 27 0.3:1 147 30 6
F3 90 36 0.4:1 138 30 6
F4 90 45 0.56:1 129 30 6
F5 90 54 0.6:1 120 30 6
F6 90 63 0.7:1 111 30 6
F7 90 72 0.8:1 102 30 6
F8 90 90 1:1 84 30 6
F9 90 120 1.33:1 54 30 6
F10 90 140 1.56:1 34 30 6
F11 90 150 1.67:1 24 30 6
Table 2: Physicochemical properties of the prepared tablets
Formula Tablet weight* (mg) Hardness* kg/cm3 Disintegration time* (min) Drug content* (%) Friability* (%)
F1 298±0.7 5.1±1.1 0.5±0.02 99.97±0.56 0.162±0.1
F2 299±0.2 5.3±0.1 0.6±0.015 99.54±0.82 0.145±0.12
F3 301±0.2 5.6±0.6 0.6±0.02 98.57±1.01 0.072±0.31
F4 300±0.1 5.2±0.3 0.8±0.01 99.39±1.31 0.095±0.26
F5 299±0.7 4.8±0.1 1.1±0.01 98.92±1.21 0.167±0.36
F6 300±0.5 5.3±0.2 1.5±0.03 101.1±1.08 0.091±0.19
F7 303±0.1 5.9±0.2 1.7±0.01 98.65±1.28 0.252±0.1
F8 297±0.1 5.1±0.1 2±0.02 98.79±1.07 0.089±0.16
F9 298±0.7 5.2±0.1 2.5±0.02 102.1±0.65 0.292±0.36
F10 298±0.7 8.2±0.1 11±0.03 98.82±0.52 0.079±0.19
F11 298±0.7 8.3±0.3 16±0.05 99.16±0.88 0.274±0.36
*The values represent mean±standard deviation, n=5
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with crospovidone. Int J Pharm 1998;175:17-24.
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of grinding of b-cyclodextrin and glibenclamide on tablet properties. 
Part I. In vitro. Drug Dev Ind Pharm 1996;22:1237-41.
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14. U.S. FDA. Guidance for Industry: Analytical Procedures and Methods 
Validation: Chemistry, Manufacturing and Controls Documentation; 
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Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1 Guideline.pdf.
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UPLC method for the determination of cefdinir in bulk and dosage 
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17. Krull IS, Swartz ME. Validation of chromatographic method. Pharm 
Tech 1998;22:104-19.
18. Ng LL. Reviewer Guidance: Validation of Chromatographic Method. 
FDA Center for Drug Evaluation and Research (CDER); 1994.
19. Available from: https://www.accessdata.fda.gov/scripts/cder/
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Mathad VT. Development and validation of an RP-UPLC method for 
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22. Ramesh K, Shekar CB, Khadgapathi P. Enhancement of solubility and 
rate of in vitro drug release profiles of poorly soluble ticagrelor by 
solvent evaporation solid dispersion technique. Indo Am J Pharm Res 
2015;5:3580-5.
23. Dabhi AN, Patel DM. Spray dried dispersions: A viable approach to 
improve bioavailability, ticagrelor as a model drug. World J Pharm Res 
2017;16:745-58.
24. El-maghraby MG, Ghanem FS. Preparation and evaluation of rapidly 
dissolving tablets of raloxifene hydrochloride by ternary system 
formation. Int J Pharm Pharm Sci 2016;1:127-36.
containing 1:3 ratio of ticagrelor: Gelucire 50/13 (G50/3) showed a 
dissolution rate of only 84% of ticagrelor dissolved after 30 min. These 
comparisons proved that there is a significant improvement in our 
work, especially regarding the dissolution rate Fig 6.
CONCLUSIONS
This study showed that cogrinding technique in the ratios of PVP K 
25 to ticagrelor 1:1 and 1.33 of F8 and F9 exhibited more than 92% 
of ticagrelor was dissolved after 30 min while the dissolution of pure 
ticagrelor was 22% only. These results may be due to the formation of 
a soluble complex between ticagrelor and PVP [12,24] However, in a 
point of PVP/drug ratio increased, the disintegration time increased 
suddenly which may be due to PVP binding effect [12] in the formulae 
F 10 and F 11.
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